President Barack Obama's nomination of Merrick Garland to the U.S. Supreme Court marks the beginning of what likely will be months of fighting over whether the Senate should confirm or even consider the 63-year-old appellate judge for the seat vacated by the late Antonin Scalia.
They got together. They broke up. They reconciled. The story may be a common one for couples, but not necessarily for hospitals and construction companies working on projects together.
Gov. Nikki Haley said Tuesday that she will almost certainly sign a bill banning abortion past 19 weeks in South Carolina. "I can't imagine any scenario in which I wouldn't sign it," she said.
There were moments in nursing school when Hina Naveed was tempted to quit, not because she couldn't do the work, but because she wondered whether, as an undocumented immigrant, she'd be allowed to get a license once she graduated.
The Massachusetts Hospital Association is adding its voice to those opposed to legalizing the recreational use of marijuana.
LifePoint Health CEO Bill Carpenter credits his legal training for helping him steer the for-profit hospital chain through a series of recent acquisitions, supported by the system's solid financial performance.
Virginia state lawmakers have thwarted an effort to loosen government oversight of new or expanded healthcare facilities in the state. Virginia is one of 36 states that maintain a certificate-of-need program.
A Chicago psychiatrist who was once the biggest prescriber in the country of the antipsychotic drug clozapine to Medicaid recipients was sentenced to nine months in federal prison Friday for accepting kickbacks in exchange for prescribing the medication.
California patients who want to take advantage of the state's new aid-in-dying law are likely to face challenges in finding cooperative providers, at least initially. But two major systems say they'll support physicians who participate.
Consumer advocates fear a proposed settlement between Amarin and the FDA may further embolden pharmaceutical companies to try marketing products for unapproved uses. It comes less than a year after a federal judge concluded off-label marketing was protected speech.
New York-based Royalty Pharma has paid $1.14 billion for a portion of the future sales of Xtandi, a prostate cancer drug.
A lawsuit filed last month against a New Jersey hospital is one of more than a dozen recent legal challenges to not-for-profit hospitals' tax exemptions in that state, following a court decision last year and a failed legislative fix.